Pharma
Currax Pharmaceuticals, LLC
1
Articles
Primary Subject
Top Role
Apr 11, 2026
First Mention
Apr 11, 2026
Last Mention
2.16
Relevance Score
Coverage Timeline
April 2026
Currax’s Nocdurna FDA Nod: $400M Branded Disruptor Upends Sleep Disorder Market Playbook
The Week
Primary Subject
Apr 11, 2026
Currax acquired the U.S. rights for a low-eight-figure upfront, industry chatter puts it around $15 million, with potential milestones carrying the price past $60 million.